Pay in 4 interest-free payments of $7.04 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
The headline read: GI tolerability dominates the side-effect picture during titration, and retatrutide's dysesthesia signal at 9-12 mg/week is the trial-level safety question that community-dose users mostly avoid by staying at 2-4 mg/week
doi: 10.1016/j.jhep.2010.10.003 215 TaylorRSTaylorRJBaylissSHagstrmHNasrPSchattenbergJMet al
This multi-receptor approach is designed to produce greater weight reduction than dual or single agonists, as demonstrated in the 2023 phase 2 trial data
Accessed March 11, 2026
10.5114/aoms.2011.20612 Arch
US$ 29.57
US$ 27.22
US$ 27.95
US$ 24.32
US$ 22.07
US$ 21.38
